SHORT REPORT

Vitamin K supplementation in cystic fibrosis

J H L van Hoorn, J J E Hendriks, C Vermeer, P Ph Forget

Arch Dis Child 2003;88:974-975

The relation between different doses of vitamin K supplementation, several bone markers, and PIVKA-II concentrations in cystic fibrosis (CF) patients compared to controls was evaluated. Results suggest that a increased vitamin K intake may have significant health benefits for children with CF.

Cystic fibrosis (CF) is the most prevalent fatal, autosomal, recessive genetic disease in white people, affecting approximately 1 in 3400 live births.

Children with CF are at high risk for developing vitamin K deficiency because of fat malabsorption. The prevalence of vitamin K deficiency in CF is not precisely known, but it is common in unsupplemented patients with pancreatic insufficiency.¹

Besides its function in blood clotting, accumulating evidence suggests that vitamin K plays a key role in improving bone health.¹ Vitamin K is a cofactor in the post-translational γ -carboxylation of glutamic acid residues (Glu) to form γ -carboxyglutamic acid (Gla) residues which are able to bind calcium. Gla containing proteins are found in the clotting cascade (vitamin K dependent clotting factors) and in bone (osteocalcin). In the absence of vitamin K, Glu residues remain undercarboxylated, resulting in a strongly decreased affinity for calcium. Undercarboxylated coagulation factors are known as PIVKAs (protein induced by vitamin K absence); notably PIVKA-II (undercarboxylated prothrombin) serves as a sensitive marker for vitamin K status. Circulating undercarboxylated osteocalcin (u-OC) is considered to be an even more sensitive marker for vitamin K status than PIVKA-II concentrations.¹ High serum u-OC concentrations are indicative of a poor bone status and are associated with low bone mineral density and increased risk of osteoporotic fractures.²⁻⁴

There is little consensus about the appropriate dose needed to prevent vitamin K deficiency in CF. Even in a large CF database (Dundee, UK) no indication can be found concerning the most appropriate dose of vitamin K to be used. Because vitamin K deficiency in CF patients may affect bone mineral status, associated complications may be prevented by adequate vitamin K supplementation.

SUBJECTS AND METHODS

In this uncontrolled study, 39 subjects were divided in four groups: 19 healthy subjects, 10 CF patients with no vitamin K (CF_{no}), six CF patients with low dose vitamin K (<0.25 mg/day = CF_{low}), and four CF patients with high dose vitamin K (≥ 1 mg/day = CF_{high}) supplementation. Inclusion criteria for CF patients were pancreas insufficiency without liver function disturbances. Serum or urine concentrations of different bone markers and serum PIVKA-II concentrations were determined in healthy subjects and in CF patients on different vitamin K supplementation. Serum concentrations of the bone formation markers osteocalcin (OC, total OC (t-OC), undercarboxylated OC (u-OC) and carboxylated

OC (c-OC)) and bone alkaline phosphatase (BAP) as well as the bone resorption marker N-terminal collagen type 1 (NTX) were determined. The bone resorption marker deoxypyridinoline (DPD) was determined in urine.

Data were analysed using the non-parametric Wilcoxon's (Mann-Whitney) rank sum test ($p < 0.05$ two sided).

RESULTS

Serum t-OC was measured in 10 controls only and was significantly higher in CF_{high} patients ($p = 0.016$) than in controls (see fig 1). Serum u-OC was significantly lower in CF_{high} patients than in controls ($p = 0.005$), CF_{no} ($p = 0.011$), and CF_{low} patients ($p = 0.033$). Serum c-OC was significantly lower in CF_{no} ($p = 0.001$) and CF_{low} patients ($p = 0.011$) than in controls, whereas c-OC was significantly higher in CF_{high} patients than in CF_{no} ($p = 0.005$) and CF_{low} patients ($p = 0.010$).

There was no significant difference in serum BAP and urinary DPD between the four groups. Serum NTX was significantly lower in CF_{no} ($p = 0.017$) and CF_{low} patients ($p = 0.020$) than in controls. Serum PIVKA-II concentrations were significantly higher in CF_{no} ($p = 0.012$) and CF_{low} patients ($p = 0.022$) than in controls (see fig 2).

DISCUSSION

High u-OC, low c-OC and raised PIVKA-II concentrations in all but CF_{high} patients suggest a vitamin K dependent carboxylation defect in CF patients. In our study only CF_{high} patients showed normal PIVKA-II concentrations suggesting that all other groups were vitamin K deficient to some degree. Hence only patients receiving a high dose (≥ 1 mg/day) of vitamin K had an adequate vitamin K status. Several studies showed that vitamin K supplementation induced a decrease of serum u-OC and may alter other bone markers such as NTX and BAP.⁵⁻⁷ Our data showed a similar tendency, with the most prominent changes in the vitamin

Figure 1 Boxplot showing total osteocalcin (t-OC in black), undercarboxylated osteocalcin (u-OC in grey), and carboxylated osteocalcin (c-OC in white) for vitamin K supplementation in CF patients, compared to healthy controls. Vitamin K supplementation is shown in three different groups: CF_{no} = no supplementation; CF_{low} = <0.25 mg/day; and CF_{high} = ≥ 1 mg/day. Significant p values are shown.

Figure 2 Boxplot showing PIVKA-II concentrations in CF patients with three different doses of vitamin K supplementation, compared to healthy controls. Significant p values are shown.

K-dependent osteocalcin. Whether the improved vitamin K status in CF_{high} patients is associated with improved bone health still remains unclear. If vitamin K supplementation resulted in increased bone formation, both bone formation markers t-OC and BAP would be expected to be high in the CF_{high} group, whereas this was only found to be the case for t-OC. Similarly, low bone resorption could be regarded as a beneficial effect. Again, our data are inconsistent, because NTX was significantly lower in the CF_{high} group, whereas DPD was not. In conclusion, our results suggest that a high dose (≥ 1 mg/day) vitamin K supplementation is needed to improve the vitamin K status of children with CF and to prevent potential vitamin K deficiency related complications. Long term (more than one year) randomised follow up

studies are required to clarify the relation between vitamin K status and bone health in CF. This aspect will be of increasing importance as CF patients grow older and have a higher frequency of pathological fractures.²⁻⁴

Authors' affiliations

J H L van Hoorn, J J E Hendriks, P Ph Forget, Department of Paediatrics, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, Netherlands

C Vermeer, Department of Biochemistry, Maastricht University, PO Box 616, 6200 MD Maastricht, Netherlands

Correspondence to: Dr J J E Hendriks, Department of Paediatrics, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, Netherlands; jhe@paed.azm.nl

Accepted 11 March 2003

REFERENCES

- 1 **Rashid M**, Durie P, Andrew M, *et al*. Prevalence of vitamin K deficiency in cystic fibrosis. *Am J Clin Nutr* 1999;**70**:378–82.
- 2 **Weber P**. Vitamin K and bone health. *Nutrition* 2001;**17**:880–7.
- 3 **Sokoll LJ**, Sadowski JA. Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. *Am J Clin Nutr* 1996;**63**:566–73.
- 4 **Binkley NC**, Krueger DC, Engelke JA, *et al*. Vitamin K supplementation reduces serum concentrations of under- γ -carboxylated osteocalcin in healthy young and elderly adults. *Am J Clin Nutr* 2000;**72**:1523–8.
- 5 **Beker LT**, Ahrens RA, Fink RJ, *et al*. Effect of vitamin K1 supplementation on vitamin k status in cystic fibrosis patients. *J Pediatr Gastroenterol Nutr* 1997;**24**:512–17.
- 6 **Wilson DC**, Rashid M, Durie PR, *et al*. Treatment of vitamin K deficiency in cystic fibrosis: effectiveness of a daily fat-soluble vitamin combination. *J Pediatr* 2001;**138**:851–5.
- 7 **Baroncelli GI**, De Luca F, Magazzù G, *et al*. Bone demineralization in CF: evidence of imbalance between bone formation and degradation. *Pediatr Res* 1997;**41**:397–403.